Ensysce Biosciences Inc
ENSC
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.74M
Close$
$0.16
61.1% downside
Current Fair Value
61.1% downsideOvervalued by 61.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.74 Million |
|---|---|
| Enterprise Value | $5.26 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.98 |
| Beta | 0.9 |
| Outstanding Shares | 13,035,632 |
Return
| Return on Equity | 1614.94% |
|---|---|
| Return on Assets | -426.88% |
| Return on Invested Capital | 1136.97% |
Valuation & Multiples
| P/E Ratio | -0.14 |
|---|---|
| PEG | -0.28 |
| Price to Sales | - |
| Price to Book Ratio | -0.4 |
| Enterprise Value to Revenue | 3.17 |
| Enterprise Value to EBIT | -0.42 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -0.25 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$1.20 M
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
$1.20 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Ensysce Biosciences Inc
4 employees